secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001600620-24-000027
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia terminates EVP R&D Volker Knappertz in restructuring
------------------------------------------------------------

- Dr. Volker Knappertz, EVP R&D, to be terminated as part of Aurinia's Feb 15 restructuring.
- Severance includes 12 months base salary, accrued vacation, performance bonus payout.
- Eligible for medical, dental, vision benefits for up to 12 months if release is provided.
- Employment agreement terms filed as Exhibit 10.18 to 2023 10-K on Feb 15, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062024000027/0001600620-24-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062024000027/auph-20240227.htm
  HTML page:      https://secwatch.observer/filing/0001600620-24-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer